Literature DB >> 6321877

Structural hepatic changes associated with cyanamide treatment: cholangiolar proliferation, fibrosis and cirrhosis.

A Moreno, J J Vazquez, L Ruizdel Arbol, F J Guillen, F Colina.   

Abstract

The authors present the clinical and histological findings in a series of 42 liver biopsies from 39 chronic alcoholics treated with cyanamide as aversion therapy. All biopsies displayed characteristic cytoplasmic inclusions in the liver-cells. Fibrosis and disruption of the parenchymal-connective tissue interface were observed in all cases. According to the severity and extension of fibrosis, three stages could be depicted: Stage I. Periportal activity cholangiolar type (ACT), which is defined by cholangiolar proliferation, fibroblastic activation and inflammatory infiltrate, which together cause a blurred appearance of the parenchymal-connective tissue junction. It is the elementary lesion and was observed alone in 26 biopsies. Stage II. Portal-to-portal linkage. It was observed in 10 biopsies, all of which also showed periportal ACT. Three of these came from patients with two biopsies in which transition from stage I (first biopsy) to stage II (second biopsy) was observed. Stage III. Nodular parenchymal regeneration, associated with changes observed in stage I and II. It was found in six patients. The histological picture resembles the biliary type of cirrhosis. There is a clear-cut correlation between the length of treatment and the stage of the hepatic lesion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321877     DOI: 10.1111/j.1600-0676.1984.tb00902.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  2 in total

Review 1.  Clinical issues related to the costs of alcoholism.

Authors:  M O Howard; R W McGuffin; A J Saxon; K L Sloan; R D Walker
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

2.  Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs?

Authors:  Carmen Verge; M Isabel Lucena; Enrique López-Torres; M José Puche-Garcia; Enrique Fraga; Manuel Romero-Gomez; Raúl J Andrade
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.